Barinthus Biotherapeutics plc
BRNSNASDAQHealthcareBiotechnology
As of Sep 18, 2026 close
- Market cap
- $30.23M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $0.51$1.41
- Volume (live)
- -
- Avg. volume (3M)
- 80.94K
BRNS was delisted on Oct 24, 2026. Data shown is historical and no longer updated.
Barinthus Biotherapeutics (BRNS) Stock Price & Financial Analysis
Barinthus Biotherapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $0.74 - $0.74 |
|---|---|
| 52-Week High | $1.41 |
| 52-Week Low | $0.51 |
| Open | $0.74 |
| Average Volume (3M) | 80.94K |
| 50-Day MA | $0.65 |
|---|---|
| 200-Day MA | $0.66 |
| 1-Year Change | −42.64% |
| Market Cap | 30.23M |
|---|---|
| Shares Outstanding | 40.85M |
| Price to Book (P/B) | 0.53 |
| EV/EBITDA | 0.52 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Sep 18, 2026. Data sources and methodology
Barinthus Biotherapeutics at a Glance
As of the Sep 18, 2026 close, Barinthus Biotherapeutics (BRNS) has a market capitalization of $30.23M. Revenue fell 100.0% year over year.
As of its latest reported balance sheet, it holds $59.30M in cash and securities against $8.57M of debt, a net cash position of $50.72M.
Barinthus Biotherapeutics does not currently pay a dividend.
The share price is down 42.6% over the past year. At $0.74 (the Sep 18, 2026 close) it sits within its 52-week range of $0.51 to $1.41, above its 200-day moving average of $0.66.
Frequently Asked Questions About Barinthus Biotherapeutics
What is the current stock price for BRNS?
As of the Sep 18, 2026 close, BRNS stock trades at $0.74. The 52-week range is $0.51–$1.41, with a day range of $0.74–$0.74.
What is the P/E ratio for BRNS?
The P/E ratio (Price-to-Earnings) for BRNS is shown in the Key Statistics section. This valuation metric helps compare Barinthus Biotherapeutics plc to industry peers.
Does BRNS pay dividends?
Barinthus Biotherapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for BRNS?
Analyst ratings and recommendations for BRNS are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.
What is the market cap of BRNS?
As of the Sep 18, 2026 close, Barinthus Biotherapeutics's market capitalization is $30.2M, classifying it as a micro-cap company. Barinthus Biotherapeutics operates in the Healthcare sector within the Biotechnology industry.